Nutritional optimization of fecal microbiota transplantation in humans: a scoping review.|https://dx.doi.org/10.1080/19490976.2024.2446378
Factors for Treatment Failure After Fecal Microbiota Transplantation in Clostridioides difficile Infection.|https://dx.doi.org/10.3390/microorganisms12122539
Pilot study of Clostridioides difficile infection (CDI) in hospitals, Italy, September to December 2022.|https://dx.doi.org/10.2807/1560-7917.ES.2025.30.1.2400206
Clostridioides difficile infection and recurrence in cancer patients (CIRCA): a multicentre, international study.|https://dx.doi.org/10.1016/j.ijid.2025.107785
Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications for Clostridioides difficile infection control.|https://dx.doi.org/10.1080/19490976.2025.2451081
Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).|https://dx.doi.org/10.1007/s40121-024-01105-y
The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.|https://dx.doi.org/10.1007/s12664-024-01717-9
Current trends in antimicrobial use and the role of antimicrobial stewardship in palliative oncology: a narrative review.|https://dx.doi.org/10.1186/s12904-025-01649-x
Phenotypic analysis of various Clostridioides difficile ribotypes reveals consistency among core processes.|https://dx.doi.org/10.1101/2025.01.10.632434
Polysaccharide lyase PL3.3 possibly potentiating Clostridioides difficile clinical symptoms based on complete genome analysis of RT046/ST35 and RT012/ST54.|https://dx.doi.org/10.1007/s10123-025-00634-x
Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against Clostridioides difficile Infection.|https://dx.doi.org/10.3390/vaccines13010021
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.|https://dx.doi.org/10.1093/ibd/izae291
A Review of Therapies for Clostridioides difficile Infection.|https://dx.doi.org/10.3390/antibiotics14010017
Prospective analysis of biomarkers associated with successful faecal microbiota transplantation in recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.1016/j.cmi.2025.01.026
Identification of two glycosyltransferases required for synthesis of membrane glycolipids in Clostridioides difficile.|https://dx.doi.org/10.1101/2025.01.14.632984
Impact of adjunct bezlotoxumab for preventing Clostridioides difficile infection recurrence in patients post - hematopoietic stem cell transplantation.|https://dx.doi.org/10.1177/10781552241310099
[The gastrointestinal microbiome - vision and mission].|https://dx.doi.org/10.1055/a-2303-3368
[Nosocomial gastrointestinal infections and Clostridioides difficile].|https://dx.doi.org/10.1055/a-2303-3321
Reactions of SleC, Its Structure and Inhibition in Mitigation of Spore Germination in Clostridioides difficile.|https://dx.doi.org/10.1021/jacs.4c14976
Clostridioides difficile recovered from hospital patients, livestock and dogs in Nigeria share near-identical genome sequences.|https://dx.doi.org/10.1099/mgen.0.001342
Gastroenterological Surgery and Management of Clostridioides difficile Infection: A Review.|https://dx.doi.org/10.23922/jarc.2024-078
Rare Presentation of Splenic Abscess Secondary to Clostridioides difficile Infection in a Patient With Systemic Sclerosis: A Case Report.|https://dx.doi.org/10.7759/cureus.76754
